Loading…
Highlights in Resistance Mechanism Pathways for Combination Therapy
Combination chemotherapy has been a mainstay in cancer treatment for the last 60 years. Although the mechanisms of action and signaling pathways affected by most treatments with single antineoplastic agents might be relatively well understood, most combinations remain poorly understood. This review...
Saved in:
| Published in: | Cells (Basel, Switzerland) Switzerland), 2019-08, Vol.8 (9), p.1013 |
|---|---|
| Main Authors: | , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c544t-b211554662507055ef9aa59ec60ecddf598c34585f66bd89f172878f0fbe85423 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c544t-b211554662507055ef9aa59ec60ecddf598c34585f66bd89f172878f0fbe85423 |
| container_end_page | |
| container_issue | 9 |
| container_start_page | 1013 |
| container_title | Cells (Basel, Switzerland) |
| container_volume | 8 |
| creator | Delou, João M A Souza, Alana S O Souza, Leonel C M Borges, Helena L |
| description | Combination chemotherapy has been a mainstay in cancer treatment for the last 60 years. Although the mechanisms of action and signaling pathways affected by most treatments with single antineoplastic agents might be relatively well understood, most combinations remain poorly understood. This review presents the most common alterations of signaling pathways in response to cytotoxic and targeted anticancer drug treatments, with a discussion of how the knowledge of signaling pathways might support and orient the development of innovative strategies for anticancer combination therapy. The ultimate goal is to highlight possible strategies of chemotherapy combinations based on the signaling pathways associated with the resistance mechanisms against anticancer drugs to maximize the selective induction of cancer cell death. We consider this review an extensive compilation of updated known information on chemotherapy resistance mechanisms to promote new combination therapies to be to discussed and tested. |
| doi_str_mv | 10.3390/cells8091013 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_6cfa520b675d41ff99a05cf469709d35</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_6cfa520b675d41ff99a05cf469709d35</doaj_id><sourcerecordid>2548347415</sourcerecordid><originalsourceid>FETCH-LOGICAL-c544t-b211554662507055ef9aa59ec60ecddf598c34585f66bd89f172878f0fbe85423</originalsourceid><addsrcrecordid>eNpdkd1rFDEUxYNYbGn75rMM-OKDa_N18_EiyKK2UKlIfQ6ZTLKTZSZZk9nK_vfOurVsDVxyyT38OLkHodcEf2BM4yvnh6EqrAkm7AU6o1iyBedYvzzqT9FlrWs8H0UEwfAKnTLCFWZKn6HldVz1w1xTbWJqfvga62ST880373qbYh2b73bqf9tdbUIuzTKPbUx2ijk1970vdrO7QCfBDtVfPt7n6OeXz_fL68Xt3deb5afbhQPOp0VLCQHgQlDAEgP4oK0F7Z3A3nVdAK0c46AgCNF2SgciqZIq4NB6BZyyc3Rz4HbZrs2mxNGWnck2mr8PuayMLVN0gzfCBQsUt0JCx0kIWlsMLnChJdYdg5n18cDabNvRd86nqdjhGfT5JMXerPKDEVLOi9ybefcIKPnX1tfJjLHu47DJ5201lCoOAAKzWfr2P-k6b0uaV2UocMW45GTv6P1B5UqutfjwZIZgsw_bHIc9y98cf-BJ_C9a9ge5OKRz</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2548347415</pqid></control><display><type>article</type><title>Highlights in Resistance Mechanism Pathways for Combination Therapy</title><source>Access via ProQuest (Open Access)</source><source>PubMed Central</source><creator>Delou, João M A ; Souza, Alana S O ; Souza, Leonel C M ; Borges, Helena L</creator><creatorcontrib>Delou, João M A ; Souza, Alana S O ; Souza, Leonel C M ; Borges, Helena L</creatorcontrib><description>Combination chemotherapy has been a mainstay in cancer treatment for the last 60 years. Although the mechanisms of action and signaling pathways affected by most treatments with single antineoplastic agents might be relatively well understood, most combinations remain poorly understood. This review presents the most common alterations of signaling pathways in response to cytotoxic and targeted anticancer drug treatments, with a discussion of how the knowledge of signaling pathways might support and orient the development of innovative strategies for anticancer combination therapy. The ultimate goal is to highlight possible strategies of chemotherapy combinations based on the signaling pathways associated with the resistance mechanisms against anticancer drugs to maximize the selective induction of cancer cell death. We consider this review an extensive compilation of updated known information on chemotherapy resistance mechanisms to promote new combination therapies to be to discussed and tested.</description><identifier>ISSN: 2073-4409</identifier><identifier>EISSN: 2073-4409</identifier><identifier>DOI: 10.3390/cells8091013</identifier><identifier>PMID: 31480389</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>ABC transporters ; Antineoplastic Agents - pharmacology ; Antineoplastic Agents - therapeutic use ; Antineoplastic Combined Chemotherapy Protocols - pharmacology ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Antitumor agents ; Cancer therapies ; Cell cycle ; Cell death ; Chemoresistance ; Chemotherapy ; Clinical trials ; cytotoxic chemotherapy ; Cytotoxicity ; Drug resistance ; Drug Resistance, Neoplasm ; drugs mechanisms of action ; Enzymes ; FDA approval ; hallmarks of cancer ; Homeostasis ; Humans ; Leukemia ; Metabolism ; Mutation ; Neoplasms - drug therapy ; Pharmaceutical industry ; resistance mechanisms ; Review ; Signal transduction ; Signal Transduction - drug effects ; targeted therapy</subject><ispartof>Cells (Basel, Switzerland), 2019-08, Vol.8 (9), p.1013</ispartof><rights>2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2019 by the authors. 2019</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c544t-b211554662507055ef9aa59ec60ecddf598c34585f66bd89f172878f0fbe85423</citedby><cites>FETCH-LOGICAL-c544t-b211554662507055ef9aa59ec60ecddf598c34585f66bd89f172878f0fbe85423</cites><orcidid>0000-0003-2866-4223 ; 0000-0003-1141-5351</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2548347415/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2548347415?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31480389$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Delou, João M A</creatorcontrib><creatorcontrib>Souza, Alana S O</creatorcontrib><creatorcontrib>Souza, Leonel C M</creatorcontrib><creatorcontrib>Borges, Helena L</creatorcontrib><title>Highlights in Resistance Mechanism Pathways for Combination Therapy</title><title>Cells (Basel, Switzerland)</title><addtitle>Cells</addtitle><description>Combination chemotherapy has been a mainstay in cancer treatment for the last 60 years. Although the mechanisms of action and signaling pathways affected by most treatments with single antineoplastic agents might be relatively well understood, most combinations remain poorly understood. This review presents the most common alterations of signaling pathways in response to cytotoxic and targeted anticancer drug treatments, with a discussion of how the knowledge of signaling pathways might support and orient the development of innovative strategies for anticancer combination therapy. The ultimate goal is to highlight possible strategies of chemotherapy combinations based on the signaling pathways associated with the resistance mechanisms against anticancer drugs to maximize the selective induction of cancer cell death. We consider this review an extensive compilation of updated known information on chemotherapy resistance mechanisms to promote new combination therapies to be to discussed and tested.</description><subject>ABC transporters</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Antineoplastic Combined Chemotherapy Protocols - pharmacology</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Antitumor agents</subject><subject>Cancer therapies</subject><subject>Cell cycle</subject><subject>Cell death</subject><subject>Chemoresistance</subject><subject>Chemotherapy</subject><subject>Clinical trials</subject><subject>cytotoxic chemotherapy</subject><subject>Cytotoxicity</subject><subject>Drug resistance</subject><subject>Drug Resistance, Neoplasm</subject><subject>drugs mechanisms of action</subject><subject>Enzymes</subject><subject>FDA approval</subject><subject>hallmarks of cancer</subject><subject>Homeostasis</subject><subject>Humans</subject><subject>Leukemia</subject><subject>Metabolism</subject><subject>Mutation</subject><subject>Neoplasms - drug therapy</subject><subject>Pharmaceutical industry</subject><subject>resistance mechanisms</subject><subject>Review</subject><subject>Signal transduction</subject><subject>Signal Transduction - drug effects</subject><subject>targeted therapy</subject><issn>2073-4409</issn><issn>2073-4409</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNpdkd1rFDEUxYNYbGn75rMM-OKDa_N18_EiyKK2UKlIfQ6ZTLKTZSZZk9nK_vfOurVsDVxyyT38OLkHodcEf2BM4yvnh6EqrAkm7AU6o1iyBedYvzzqT9FlrWs8H0UEwfAKnTLCFWZKn6HldVz1w1xTbWJqfvga62ST880373qbYh2b73bqf9tdbUIuzTKPbUx2ijk1970vdrO7QCfBDtVfPt7n6OeXz_fL68Xt3deb5afbhQPOp0VLCQHgQlDAEgP4oK0F7Z3A3nVdAK0c46AgCNF2SgciqZIq4NB6BZyyc3Rz4HbZrs2mxNGWnck2mr8PuayMLVN0gzfCBQsUt0JCx0kIWlsMLnChJdYdg5n18cDabNvRd86nqdjhGfT5JMXerPKDEVLOi9ybefcIKPnX1tfJjLHu47DJ5201lCoOAAKzWfr2P-k6b0uaV2UocMW45GTv6P1B5UqutfjwZIZgsw_bHIc9y98cf-BJ_C9a9ge5OKRz</recordid><startdate>20190830</startdate><enddate>20190830</enddate><creator>Delou, João M A</creator><creator>Souza, Alana S O</creator><creator>Souza, Leonel C M</creator><creator>Borges, Helena L</creator><general>MDPI AG</general><general>MDPI</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M7P</scope><scope>P64</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0003-2866-4223</orcidid><orcidid>https://orcid.org/0000-0003-1141-5351</orcidid></search><sort><creationdate>20190830</creationdate><title>Highlights in Resistance Mechanism Pathways for Combination Therapy</title><author>Delou, João M A ; Souza, Alana S O ; Souza, Leonel C M ; Borges, Helena L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c544t-b211554662507055ef9aa59ec60ecddf598c34585f66bd89f172878f0fbe85423</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>ABC transporters</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Antineoplastic Combined Chemotherapy Protocols - pharmacology</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Antitumor agents</topic><topic>Cancer therapies</topic><topic>Cell cycle</topic><topic>Cell death</topic><topic>Chemoresistance</topic><topic>Chemotherapy</topic><topic>Clinical trials</topic><topic>cytotoxic chemotherapy</topic><topic>Cytotoxicity</topic><topic>Drug resistance</topic><topic>Drug Resistance, Neoplasm</topic><topic>drugs mechanisms of action</topic><topic>Enzymes</topic><topic>FDA approval</topic><topic>hallmarks of cancer</topic><topic>Homeostasis</topic><topic>Humans</topic><topic>Leukemia</topic><topic>Metabolism</topic><topic>Mutation</topic><topic>Neoplasms - drug therapy</topic><topic>Pharmaceutical industry</topic><topic>resistance mechanisms</topic><topic>Review</topic><topic>Signal transduction</topic><topic>Signal Transduction - drug effects</topic><topic>targeted therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Delou, João M A</creatorcontrib><creatorcontrib>Souza, Alana S O</creatorcontrib><creatorcontrib>Souza, Leonel C M</creatorcontrib><creatorcontrib>Borges, Helena L</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Biological Science Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Access via ProQuest (Open Access)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Cells (Basel, Switzerland)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Delou, João M A</au><au>Souza, Alana S O</au><au>Souza, Leonel C M</au><au>Borges, Helena L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Highlights in Resistance Mechanism Pathways for Combination Therapy</atitle><jtitle>Cells (Basel, Switzerland)</jtitle><addtitle>Cells</addtitle><date>2019-08-30</date><risdate>2019</risdate><volume>8</volume><issue>9</issue><spage>1013</spage><pages>1013-</pages><issn>2073-4409</issn><eissn>2073-4409</eissn><abstract>Combination chemotherapy has been a mainstay in cancer treatment for the last 60 years. Although the mechanisms of action and signaling pathways affected by most treatments with single antineoplastic agents might be relatively well understood, most combinations remain poorly understood. This review presents the most common alterations of signaling pathways in response to cytotoxic and targeted anticancer drug treatments, with a discussion of how the knowledge of signaling pathways might support and orient the development of innovative strategies for anticancer combination therapy. The ultimate goal is to highlight possible strategies of chemotherapy combinations based on the signaling pathways associated with the resistance mechanisms against anticancer drugs to maximize the selective induction of cancer cell death. We consider this review an extensive compilation of updated known information on chemotherapy resistance mechanisms to promote new combination therapies to be to discussed and tested.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>31480389</pmid><doi>10.3390/cells8091013</doi><orcidid>https://orcid.org/0000-0003-2866-4223</orcidid><orcidid>https://orcid.org/0000-0003-1141-5351</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2073-4409 |
| ispartof | Cells (Basel, Switzerland), 2019-08, Vol.8 (9), p.1013 |
| issn | 2073-4409 2073-4409 |
| language | eng |
| recordid | cdi_doaj_primary_oai_doaj_org_article_6cfa520b675d41ff99a05cf469709d35 |
| source | Access via ProQuest (Open Access); PubMed Central |
| subjects | ABC transporters Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use Antineoplastic Combined Chemotherapy Protocols - pharmacology Antineoplastic Combined Chemotherapy Protocols - therapeutic use Antitumor agents Cancer therapies Cell cycle Cell death Chemoresistance Chemotherapy Clinical trials cytotoxic chemotherapy Cytotoxicity Drug resistance Drug Resistance, Neoplasm drugs mechanisms of action Enzymes FDA approval hallmarks of cancer Homeostasis Humans Leukemia Metabolism Mutation Neoplasms - drug therapy Pharmaceutical industry resistance mechanisms Review Signal transduction Signal Transduction - drug effects targeted therapy |
| title | Highlights in Resistance Mechanism Pathways for Combination Therapy |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-20T10%3A49%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Highlights%20in%20Resistance%20Mechanism%20Pathways%20for%20Combination%20Therapy&rft.jtitle=Cells%20(Basel,%20Switzerland)&rft.au=Delou,%20Jo%C3%A3o%20M%20A&rft.date=2019-08-30&rft.volume=8&rft.issue=9&rft.spage=1013&rft.pages=1013-&rft.issn=2073-4409&rft.eissn=2073-4409&rft_id=info:doi/10.3390/cells8091013&rft_dat=%3Cproquest_doaj_%3E2548347415%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c544t-b211554662507055ef9aa59ec60ecddf598c34585f66bd89f172878f0fbe85423%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2548347415&rft_id=info:pmid/31480389&rfr_iscdi=true |